IGA

GEISSLER'S TO LAUNCH INSTACART'S SMART CARTS IN ALL STORES

Retrieved on: 
Thursday, November 2, 2023

EAST WINDSOR, Conn. and SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ -- Geissler's Supermarkets, a seven-store IGA retailer with locations in Connecticut and Massachusetts, and Instacart (NASDAQ: CART), the leading grocery technology company in North America, today announced a new partnership to bring Caper Carts, Instacart's artificial intelligence-powered (AI) smart carts, to all seven Geissler's locations, replacing a majority of their traditional shopping carts over the coming months.

Key Points: 
  • Customers will be able to use their loyalty account on the carts, giving them access to personalized promotions and savings as they shop.
  • "We see clearly the value that Caper Carts bring to our customers and our business, in the short and long term.
  • Caper Carts are part of Instacart's Connected Stores technology offerings for retailers, helping grocers bridge the online and in-store shopping experience.
  • To learn more about Caper Carts and other Connected Stores technologies, visit www.instacart.com/company/retailer-platform/connected-stores .

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Retrieved on: 
Friday, October 13, 2023

The Phase 3 program for amlitelimab in atopic dermatitis is on track to start in the first half of 2024.

Key Points: 
  • The Phase 3 program for amlitelimab in atopic dermatitis is on track to start in the first half of 2024.
  • Global Head of Research & Development, Sanofi
    “The data presented at EADV provide more detailed insight into amlitelimab’s potential as a best-in-class therapy for people with atopic dermatitis.
  • TEAEs more commonly observed with amlitelimab compared to placebo included nasopharyngitis (11.0% amlitelimab, 9.0% placebo), COVID-19 (7.7% amlitelimab, 6.4% placebo) and headache (6.1% amlitelimab, 2.6% placebo).
  • Worsening of atopic dermatitis was more commonly observed with placebo compared to amlitelimab (38.5% placebo, 17.1% amlitelimab).

DeepPower CEO Andrew Van Noy Discusses Geothermal Growth with the CEO of the International Geothermal Association

Retrieved on: 
Wednesday, October 11, 2023

During the conversation, Dr. Brommer reported that when she was appointed CEO of the IGA 6 years ago, geothermal was a “nice” and interesting technology that had small-scale impact without a “global voice”.

Key Points: 
  • During the conversation, Dr. Brommer reported that when she was appointed CEO of the IGA 6 years ago, geothermal was a “nice” and interesting technology that had small-scale impact without a “global voice”.
  • Fast forward 5 years, the industry has changed drastically and with the global directives to become carbon neutral, the industry has seen great technological progress.
  • The IGA connects the Global Geothermal Community, serving as a hub for networking opportunities aimed at promoting and supporting global geothermal development.
  • This podcast can be viewed at: https://deeppower.com/single-video.php?id=K3MDKXXujNw
    To learn more about DeepPower, please visit https://deeppower.com/index.php

Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)

Retrieved on: 
Tuesday, October 17, 2023

This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.

Key Points: 
  • This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.
  • Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) to the European Medicine Agency (EMA) through the centralized procedure, aimed at obtaining a single Marketing Authorization for the product in the European Union.
  • The EMA's rigorous evaluation process will assess the product's safety, quality, and efficacy, ultimately determining its suitability for approval within the European market.
  • This submission to the EMA is a pivotal step forward in our mission as well as a testament to our ongoing commitment to innovation.

Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1

Retrieved on: 
Friday, October 13, 2023

Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.

Key Points: 
  • Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
  • Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.
  • † More information about the Phase 3 studies: ADvocate 1: EudraCT Number 2019-002932-10; NCT04146363; ADvocate 2: EudraCT Number 2019-002933-12; NCT04178967; ADhere: EudraCT Number 2019-004300-34; NCT04250337

LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023

Retrieved on: 
Friday, October 13, 2023

DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4

Key Points: 
  • DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4
    DELTA 2 was a randomized, double-blind, cream vehicle-controlled trial.
  • Adults were randomized to either twice-daily delgocitinib cream (n=314) or cream vehicle (n=159) for 16 weeks followed by a separate 36-week extension trial.
  • “Through assessment of the DELTA 1 and DELTA 2 trial results, we aim to assess the efficacy and safety of delgocitinib cream in adults living with this hard-to-treat disease."
  • “This latest collection of clinical data for delgocitinib cream supports LEO Pharma’s unwavering commitment to addressing the critical unmet need in CHE,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.

LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)

Retrieved on: 
Friday, October 13, 2023

LEO Pharma A/S, a global leader in medical dermatology, today presented new data assessing the long-term safety and efficacy data of continuous treatment with Adtralza® (tralokinumab) over four years for moderate-to-severe atopic dermatitis (AD) in adults.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today presented new data assessing the long-term safety and efficacy data of continuous treatment with Adtralza® (tralokinumab) over four years for moderate-to-severe atopic dermatitis (AD) in adults.
  • The analysis was of participants from ECZTEND who had previously enrolled in the ECZTRA 1 and 2 phase 3 trials.
  • Again, the pattern of adverse events (AEs) was consistent with the initial placebo-controlled treatment period and with no new safety signals identified.
  • “We aim to use this long-term and real-world evidence to build upon Adtralza’s existing foundation of research.”

Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

Retrieved on: 
Wednesday, October 11, 2023

Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively.

Key Points: 
  • Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively.
  • The late-breaking data were presented today at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin.
  • View the full release here: https://www.businesswire.com/news/home/20231011848851/en/
    “While atopic dermatitis and prurigo nodularis are distinct diseases, their commonality lies in the severe, persistent itch, which leads to poor quality sleep and negatively impacts mental health.
  • Statistically significant results at week 16 and earlier time points also show nemolizumab’s rapid onset of action on itch and sleep disturbance.

Veza Introduces Next-Gen IGA Solution to Deliver Identity Security for the Enterprise

Retrieved on: 
Tuesday, October 10, 2023

Identity security is a top priority because research shows that 80% of cyberattacks leverage identity-based techniques. Organizations need processes to reduce the permissions sprawl that allows attacks to succeed. Reflecting that need, NIST has proposed the addition of “govern” to its widely-used Cybersecurity Framework (CSF)--the first update in a decade. According to Gartner® Market Guide for Identity Governance and Administration, “IGA tools have not kept up with demand for machine (device and workload) identity management capabilities, forcing companies to pursue separate solutions in many cases.” Traditional IGA products have blind spots with access because they were built for an era with dramatically fewer permissions.

Key Points: 
  • Today Veza , the identity security company, announced the launch of its Next-Gen IGA (Identity Governance and Administration) solution.
  • The solution comprises the Veza Access Control Platform and new products for provisioning and deprovisioning, access reviews, access visibility, and access intelligence.
  • Veza powers Next-Gen IGA with the Veza Access Control Platform, which ingests and analyzes authorization permission metadata from enterprise systems and organizes it into the Veza Authorization Graph.
  • Moreover, the Veza platform allows us to manage the entire lifecycle of an identity, meeting both security and compliance needs.